Dec 16 (Reuters) - IDEAYA Biosciences Inc IDYA.O:
IDEAYA ANNOUNCES DEVELOPMENT CANDIDATE NOMINATION OF IDE251, A POTENTIAL FIRST-IN-CLASS KAT6/7 DUAL INHIBITOR TARGETING 8P11 AMPLIFICATION TUMORS IN BREAST AND LUNG CANCERS
IDEAYA BIOSCIENCES INC: TARGETING IND SUBMISSION FOR IDE251 IN 2025
Source text: ID:nPn9WYll1a
Further company coverage: IDYA.O